Clinical Trials
104 trialsDonor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
FRONTIER
Miltenyi Biomedicine GmbH
ZUMA-2
Gilead Sciences
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
JKART-1
Gilead Sciences
ZUMA-2
Gilead Sciences
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma
University of Miami
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
DALY II USA/ MB-CART2019.1 for DLBCL
Miltenyi Biomedicine GmbH
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Fred Hutchinson Cancer Center
Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma
Academic and Community Cancer Research United
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Roswell Park Cancer Institute
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
City of Hope Medical Center
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
University of Nebraska
Allo HSCT Using RIC for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Vaccine Therapy Plus Sargramostim Following Chemotherapy in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
University of Nebraska
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
University of Nebraska
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute
Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
SWOG Cancer Research Network
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
The First Affiliated Hospital with Nanjing Medical University
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma
SWOG Cancer Research Network
Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
Universität des Saarlandes
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Masonic Cancer Center, University of Minnesota
Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies
M.D. Anderson Cancer Center
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Stanford University
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma
University of Wisconsin, Madison
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Roswell Park Cancer Institute
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
University of Maryland, Baltimore
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
University of Maryland, Baltimore
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Mayo Clinic
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma
Montefiore Medical Center
Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
Weill Medical College of Cornell University
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Masonic Cancer Center, University of Minnesota
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Masonic Cancer Center, University of Minnesota
S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
SWOG Cancer Research Network
Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Memorial Sloan Kettering Cancer Center